Is paliperidone approved for use as an adjunctive treatment for major depressive disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Paliperidone is NOT FDA-approved for adjunctive treatment of major depressive disorder

Paliperidone is FDA-approved only for schizophrenia (adults and adolescents ≥12 years) and schizoaffective disorder (as monotherapy or adjunctive to mood stabilizers/antidepressants), but NOT for major depressive disorder. 1

FDA-Approved Indications for Paliperidone

According to the FDA drug label, paliperidone's approved uses are strictly limited to:

  • Schizophrenia in adults and adolescents (12-17 years)
  • Schizoaffective disorder in adults (either as monotherapy OR as adjunctive therapy to mood stabilizers and/or antidepressants)

The key distinction here is that while paliperidone can be used adjunctively in schizoaffective disorder (which includes mood symptoms), this is fundamentally different from major depressive disorder 1.

FDA-Approved Atypical Antipsychotics for MDD Adjunctive Treatment

For adjunctive treatment of major depressive disorder specifically, the FDA has approved only certain atypical antipsychotics:

  • Aripiprazole (approved as augmentation for MDD) 2
  • Brexpiprazole (approved as augmentation for MDD) 3
  • Quetiapine XR (approved as augmentation for MDD) 2
  • Olanzapine/fluoxetine combination (approved for MDD) 2

Notably absent from this list is paliperidone 2.

Clinical Evidence Context

While paliperidone has been studied in bipolar disorder with some efficacy signals 4, 5, and research suggests it may have antidepressant properties in preclinical studies 6, no clinical trials have established its efficacy or safety specifically for major depressive disorder 2. The 2012 systematic review explicitly noted that "no clinical trials were found for off-label use" of paliperidone in depression-related conditions 2.

Clinical Implications

If you are considering adjunctive treatment for a patient with treatment-resistant major depressive disorder, use FDA-approved options: aripiprazole, brexpiprazole, quetiapine XR, or olanzapine/fluoxetine combination 7, 8, 7, 9, 10. These have established efficacy and safety data specifically in MDD populations.

Using paliperidone for MDD would constitute off-label use without supporting clinical trial evidence, exposing patients to risks (extrapyramidal symptoms, hyperprolactinemia, metabolic effects, orthostatic hypotension) 1 without demonstrated benefit in this population.

References

Related Questions

Which mood stabilizer is best combined with Invega (paliperidone)?
Is the current medication regimen appropriate for a patient with major depressive disorder, recurrent, moderate (F33.1), unspecified anxiety disorder (F41.9), and unspecified agoraphobia (F40.00) who is taking sertraline 150 mg orally daily, bupropion extended‑release 300 mg orally daily, aripiprazole 2 mg orally daily, buspirone 10 mg twice daily, mirtazapine 7.5 mg orally as needed for sleep, and propranolol 10 mg orally as needed for situational social anxiety, given that mood has plateaued with low‑grade depressive symptoms, increased irritability, impatience, and episodes of disproportionate anger?
For a 77-year-old male with anxiety and depression who is taking lamotrigine (Lamictal) 200 mg daily, mirtazapine (Remeron) 15 mg at bedtime, and duloxetine 30 mg in the morning and 60 mg at bedtime, should a low‑dose atypical antipsychotic be added to augment his regimen, and what dose and monitoring are recommended?
Can on‑abotulinumtoxinA be used as an adjunctive treatment for adults with treatment‑resistant major depressive disorder, and what are the appropriate dosing, contraindications, and monitoring guidelines?
I have major depressive disorder and anxiety, and I'm taking venlafaxine (Effexor) 75 mg daily and buspirone (Buspar) 10 mg twice daily, but I'm experiencing headache and excessive sleepiness; how should I manage these side effects?
At what gestational age is diclofenac contraindicated during pregnancy?
Is there evidence that the beetroot supplement Super Beets (beetroot powder) can lower blood pressure?
What infections are associated with daratumumab therapy in multiple myeloma, and how should they be monitored and managed?
Can clonidine be added safely to a patient already taking atorvastatin 10 mg daily and losartan 50 mg daily?
Can I use Bactroban (mupirocin) for my penile infection after topical ketoconazole (Ketaderm) and clotrimazole have failed?
Please review the laboratory panel of a patient with chronic kidney disease stage 4 (estimated glomerular filtration rate (eGFR) ≈ 16 mL/min/1.73 m²) that shows elevated serum creatinine, elevated blood urea nitrogen (BUN), low serum carbon dioxide (CO₂) indicating metabolic acidosis, borderline low calcium, and otherwise normal electrolytes.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.